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Abstract
The establishment of efficient gene delivery to target human tissue is a major obstacle for transition
of gene therapy from the pre-clinical phases to the clinic. The poor long-term patency rates for
coronary artery bypass grafting (CABG) is a major clinical problem that lacks an effective and
proven pharmacological intervention. Late vein graft failure occurs due to neointima formation and
accelerated atherosclerosis. Since CABG allows a clinical window of opportunity to genetically
modify vein ex vivo prior to grafting it represents an ideal opportunity to develop gene-based
therapies. Adenoviral vectors have been frequently used for gene delivery to vein ex vivo and pre-
clinical studies have shown effective blockade in neointima development by overexpression of
candidate therapeutic genes. However, high titers of adenovirus are required to achieve sufficient
gene delivery to provide therapeutic benefit. Improvement in the uptake of adenovirus into the
vessel wall would therefore be of benefit. Here we determined the ability of an adenovirus serotype
5 vector genetically-engineered with the RGD-4C integrin targeting peptide inserted into the HI
loop (Ad-RGD) to improve the transduction of human saphenous vein smooth muscle cells
(HSVSMC), endothelial cells (HSVEC) and intact saphenous vein compared to a non-modified virus
(Ad-CTL). We exposed each cell type to virus for 10, 30 or 60 mins and measured transgene at 24
h post infection. For both HSVSMC and HSVEC Ad-RGD mediated increased transduction, with
the largest increases observed in HSVSMC. When the experiments were repeated with intact
human saphenous vein (the ultimate clinical target for gene therapy), again Ad-RGD mediated
higher levels of transduction, at all clinically relevant exposures times (10, 30 and 60 mins
tissue:virus exposure). Our study demonstrates the ability of peptide-modified Ad vectors to
improve transduction to human vein graft cells and tissue and has important implications for gene
therapy for CABG.
Text
Long term patency rates for CABG using autologous
saphenous vein are poor, showing 1, 5 and 10 years post-
CABG rates of 93%, 74% and 41%, respectively [1] and
therefore represent a significant clinical problem. Long-
term failures are due to neointima formation and super-
imposed atherosclerosis [2-4], a pathology that lacks a
suitably efficient pharmacological therapy. Significant
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contributions of vascular smooth muscle cell (SMC) pro-
liferation and migration have been documented [2-4].
Anti-proliferative strategies are in phase III clinical trial
using decoy oligonucleotides to the transcription factor
E2F, a strategy that has shown considerable promise pre-
clinically [5,6] and also in early stage human trials [7].
We, and others have adopted the alternate strategy of gene
therapy to prevent CABG failure [8]. CABG is an "ideal"
clinical scenario for gene therapy since saphenous vein
can be genetically modified ex vivo following leg harvest-
ing and prior to coronary grafting. This unique "clinical
window" has clear safety advantages over in vivo gene
delivery since excess vector can be removed from the graft
prior to coronary grafting. However, the clinical window
is short (likely 10–60 minutes) and therefore necessitates
the use of an efficient vector system for gene delivery. Ade-
noviral vectors have proven efficient for gene delivery in
this context [9] although high titers are required to pro-
vide sufficient levels of gene delivery to achieve therapeu-
tic gain using transgenes such as tissue inhibitor of
metalloproteinases-3 [9], endothelial nitric oxide syn-
thase [10] and p53 [11]. The latter study defined the
rationale behind use of adenoviral vectors since long-term
benefit on graft remodelling was shown at 3 months, even
though the virus was only present for 2–4 weeks post
grafting [11]. Any improvement in gene delivery above
that mediated by adenoviral serotype 5 vectors would be
very encouraging for clinical translation of pre-clinical
therapies. To this end, a number of strategies have
emerged including fiber switching (pseudotyping) and
modification of adenovirus type 5 fibers with targeting
peptides. Pseudotyping the fiber from adenovirus sero-
type 16, which binds CD46 [12], dramatically improves
transduction to vascular cells including intact human
saphenous vein allowing lower doses of vector to be used
to achieve attractive levels of gene delivery to grafts ex vivo
[13]. Likewise, gene delivery to vascular smooth muscle
cells can be enhanced by incorporation of cell targeting
peptides isolated by phage display into the HI loop of the
adenovirus fiber [14], the preferred site for peptide inser-
tion [15]. In the context of improved gene delivery medi-
ated by the RGD-4C peptide, which was isolated by phage
display and targets αv integrins [16], this has been shown
for rabbit grafts [17] although the vast majority of data is
based on gene delivery for cancer [18]. Since SMC show
poor coxsackie and adenovirus receptor (CAR) availability
[19], it is particularly relevant that the RGD-4C peptide
may circumvent CAR deficiency on target cells to improve
levels of transduction. In this study, we assess the ability
of RGD-4C-modified adenovirus serotype 5 vectors to
enhance gene delivery to human saphenous vein SMC
and EC as well as to intact human saphenous vein ex vivo,
the ultimate clinical target.
HSVEC were obtained by enzymatic collagenase digestion
of human saphenous vein and maintained in endothelial
cell complete media (TCS CellWorks, UK) supplemented
with 20% (v/v) foetal calf serum (FCS; PAA laboratories,
UK). HSVSMC were grown from medial explants from the
same material and maintained in Dulbecco's modified
Eagle's medium (DMEM) with 4500 mg/l glucose supple-
mented with 20% (v/v) FCS and 100 IU/ml penicillin,
100 µg/ml streptomycin and 2 mmol/l L-Glutamine. All
cells were grown in a humidified atmosphere with 5%
CO2 at 37°C. Cells were plated to reach 80% confluence
24 hours later. HSVEC or HSVSMC were infected in 96
well plates with increasing doses [plaque forming units
(pfu) / cell] of Ad vectors for 10, 30, 60 mins at 37°C. The
cells were washed twice in PBS and the media changed. 24
hours post-infection, the cells were again washed in PBS,
lysed in PBS/0.2% Triton-X-100 and transduction quanti-
fied using the Wallac 1420 (Victor2) Multilabel Counter
with recombinant eGFP (Clontech, Basingstoke, UK) as a
standard. Reporter gene expression was normalised for
total protein using the bicinchoninic acid (BCA) protein
assay (Perbio, UK) with bovine serum albumin as stand-
ard, measured using a VICTOR2 plate reader. Exposure of
HSVEC to Ad-CTL or Ad-RGD [50 plaque forming units
(pfu) / cell] resulted in a time-dependent increase in the
level of transduction (Figure 1A). At each time point stud-
ied (10, 30 or 60 mins), Ad-RGD mediated a significantly
enhanced level of transgene expression compared to Ad-
CTL (Figure 1A). Fluorescent microscopy demonstrated
that control levels of infection with Ad-CTL were relatively
high in HSVEC but further enhanced using the RGD-mod-
ified Ad (Figure 1A) at all time points tested. This is con-
sistent with HSVEC expressing moderate CAR levels
[14,19] allowing transduction of cells by Ad-CTL but the
RGD-4C vector can further improve virus uptake. In
HSVSMC, Ad-RGD again mediated a marked and signifi-
cant enhancement in levels of transgene expression at all
time points studied (Figure 1B). HSVSMC were much less
permissive to non-modified Ad-CTL infection (Figure 1B),
consistent with our previous observations [14], but
enhanced with Ad-RGD to near 100% transduction in
HSVSMC by fluorescence microscopy (Figure 1B). Again,
this effect was evident at all virus:cell exposure time points
– 10, 30 and 60 mins. For both HSVEC and SMC similar
RGD-4C-mediated increases were observed with different
viral doses (10 and 100 pfu/cell; not shown) thereby
showing both time- and dose-dependence.
Based on the above we therefore assessed transduction in
intact human saphenous vein. In order to quantify trans-
gene expression accurately in tissue extracts we used luci-
ferase-expressing viruses. Intact human saphenous veins
were cleaned of surrounding connective tissue and cut
into rings 3–4 mm in length. During preparation and
infection, veins were maintained in wash medium (RPMIGenetic Vaccines and Therapy 2004, 2:14 http://www.gvt-journal.com/content/2/1/14
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supplemented with 100 IU/ml penicillin, 100 µg/ml
streptomycin and 2 mmol/l L-glutamine). Individual vein
rings were incubated with Ad vectors for 10, 30 or 60 min-
utes (1 × 109 pfu / ring) before being washed twice in PBS
and maintained in organ culture for 5 days. Rings were
maintained in wash medium supplemented with 30% (v/
v) FCS. Vein rings were snap frozen in liquid nitrogen and
homogenised using a mortar and pestle for determination
of reporter gene expression 5 days post-infection. Ex vivo
homogenates were suspended in 100 µL reporter lysis
buffer (RLB) and kept on ice for 1 hour before superna-
tants were analysed for luciferase expression using the
Luciferase Assay System (Promega). 96 well plates were
prepared using 10 µL/well of homogenate suspension
diluted to a total volume of 100 µL with RLB. 100 µL of
Luciferase Assay Reagent was added to each well and the
plate immediately read for 10 seconds per well. Detection
was achieved using a Wallac 1420 (VICTOR2) Multilabel
Counter with recombinant luciferase (Promega) as a
standard and normalised for total protein. Ad-RGDLuc
mediated a time-dependent increase in the level of trans-
gene expression that was evident at all exposure times
studied – 10, 30 and 60 minutes (Figure 1C). This demon-
strates that the RGD-4C-modification of Ad vectors can
increase transduction to human saphenous vein, espe-
cially at short exposure times. The kinetics of virus bind-
ing in relation to time is therefore improved through the
RGD-4C peptide and has direct implications for the
design of gene therapy vectors for use in human CABG
gene therapy procedures in the future. Although we have
previously shown that non-modified Ad vectors transduce
both endothelial and smooth muscle cells during graft
Transduction of saphenous vein cells and intact tissue Figure 1
Transduction of saphenous vein cells and intact tissue. Ad-CTL and Ad-RGD expressing eGFP were incubated with (A) HSVEC 
and (B) HSVSMC for different times and gene expression quantified and normalised to protein. Representative fluorescent 
images are shown. (C) Intact human saphenous vein was incubated with luciferase-expressing vectors and expression quanti-
fied. *Indicates p < 0.05 vs Ad-CTL.Publish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
Genetic Vaccines and Therapy 2004, 2:14 http://www.gvt-journal.com/content/2/1/14
Page 4 of 4
(page number not for citation purposes)
gene delivery [9], and here show increased transduction of
both cell types in vitro with RGD-modification, it will be
important to fully define the uptake of the RGD-modified
virus in the intact vein at the cellular level by immunote-
chniques. In broader terms, the design and tailoring of
viruses for individual cardiovascular gene therapy applica-
tions is an important aspect of translation from pre-clini-
cal to clinical gene therapy.
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